awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38983310-D8CBE80B-C641-4222-A0B2-05F5D631D64A
Q38983310-D8CBE80B-C641-4222-A0B2-05F5D631D64A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38983310-D8CBE80B-C641-4222-A0B2-05F5D631D64A
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.
P2860
Q38983310-D8CBE80B-C641-4222-A0B2-05F5D631D64A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38983310-D8CBE80B-C641-4222-A0B2-05F5D631D64A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e79dd9af18e7727d21beb32fbdbc8366ed5d98b9
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer